Trials / Completed
CompletedNCT02218034
Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-190168 Formulation 1 | AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| DRUG | AGN-190168 Formulation 2 | AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| DRUG | tazarotene gel 0.1% | Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| DRUG | tazarotene cream 0.1% | Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2014-08-15
- Last updated
- 2015-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02218034. Inclusion in this directory is not an endorsement.